Patients' preferences for 3 months versus 6 months of adjuvant chemotherapy (ACT) for colon cancer in the SCOT trial: what survival benefits make longer chemotherapy worthwhile?

被引：2
|
作者：
Blinman, Prunella Louise
Martin, Andrew James
Jefford, Michael
Goldstein, David
Boadle, David
Morris, Michelle Frances
Tebbutt, Niall C.
Aiken, Christine
Paul, James
Segelov, Eva
Haydon, Andrew Mark
Iveson, Tim
Stockler, Martin R.
机构：
[1] Concord Repatriat Gen Hosp, Concord, NSW, Australia
[2] Univ Sydney, NHMRC Clin Trials Ctr, Sydney, NSW, Australia
[3] Peter MacCallum Canc Ctr, Div Canc Med, Melbourne, Australia
[4] Prince Wales Hosp, Randwick, NSW, Australia
[5] Royal Hobart Hosp, Hobart, Tas, Australia
[6] Sunshine Coast Canc Serv, Nambour, Australia
[7] Heidelberg Repatriat Hosp, Olivia Newton John Canc & Wellness Ctr, Heidelberg, Australia
[8] NHMRC Clin Trials Ctr, Sydney, NSW, Australia
[9] Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland
[10] Monash Univ, Melbourne, Australia
[11] Monash Hlth, Melbourne, Australia
[12] Alfred Hosp, Melbourne, Australia
[13] Univ Hosp Southampton NHS Fdn Trust, Southampton, Hants, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.3602
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3602
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Patients' Preferences for 3 Versus 6 Months of Adjuvant Chemotherapy (ACT) for Colon Cancer in the SCOT Trial: What Survival Benefits Make Longer Chemotherapy Worthwhile?
    Blinman, P.
    Martin, A.
    Jefford, M.
    Goldstein, D.
    Boadle, D.
    Morris, M.
    Tebbutt, N.
    Aiken, C.
    Segelov, E.
    Paul, J.
    Haydon, A.
    Iveson, T.
    Stockler, M.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 51 - 51
  • [2] Patients' Preferences for 3 Months vs 6 Months of Adjuvant Chemotherapy for Colon Cancer
    Blinman, Prunella
    Martin, Andrew
    Jefford, Michael
    Goldstein, David
    Boadle, David
    Morris, Michelle
    Tebbutt, Niall
    Aiken, Christine
    Harkin, Andrea
    Segelov, Eva
    Haydon, Andrew
    Iveson, Tim
    Stockler, Martin R.
    JNCI CANCER SPECTRUM, 2021, 5 (01)
  • [3] Adjuvant chemotherapy for early colon cancer: What survival benefits make it worthwhile?
    Blinman, Prunella
    Duric, Vlatka
    Nowak, Anna K.
    Beale, Philip
    Clarke, Stephen
    Briscoe, Karen
    Boyce, Adam
    Goldstein, David
    Hudson, Malcolm
    Stockler, Martin
    EUROPEAN JOURNAL OF CANCER, 2010, 46 (10) : 1800 - 1807
  • [4] Patients' preferences for adjuvant chemotherapy (ACT) in early colon cancer (ECC): What makes it worthwhile?
    Blinman, P. L.
    Duric, V. M.
    Nowak, A. K.
    Beale, P.
    Clarke, S. J.
    Briscoe, K.
    Boyce, A.
    Goldstein, D.
    Hudson, M.
    Stockler, M. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [5] Colon Cancer: 3 Months of adjuvant Chemotherapy as effective as 6?
    Andres, Ulrike
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2018, 56 (08): : 888 - 888
  • [6] Adjuvant chemotherapy in colon cancer: 6 months better than 3?
    Alisher, Z.
    Djuraev, F. M.
    Abdujapparov, A. S.
    ANNALS OF ONCOLOGY, 2024, 35 : S10 - S10
  • [7] Preferences for adjuvant chemotherapy (ACT) in early breast cancer: The benefits needed to make extended treatment with docetaxel, doxorubicin, and CMF worthwhile
    Duric, V.
    Francis, P.
    Simard-Lebrun, J.
    Chan, A.
    Chirgwin, J.
    Harvey, V.
    Sullivan, A.
    Simes, R.
    Coates, A. S.
    Stockler, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [8] The hard road to data interpretation: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer?
    Sobrero, A.
    Grothey, A.
    Iveson, T.
    Labianca, R.
    Yoshino, T.
    Taieb, J.
    Maughan, T.
    Buyse, M.
    Andre, T.
    Meyerhardt, J.
    Shields, A. F.
    Souglakos, I
    Douillard, J-Y
    Cervantes, A.
    ANNALS OF ONCOLOGY, 2018, 29 (05) : 1099 - 1107
  • [9] Overall survival with 3 or 6 months of adjuvant chemotherapy in Italian TOSCA phase 3 randomised trial
    Petrelli, F.
    Rulli, E.
    Labianca, R.
    Lonardi, S.
    Rosati, G.
    Dotti, K.
    Ronzoni, M.
    Pella, N.
    Pusceddu, V
    Banzi, M.
    Zampino, M. G.
    Yasmina, M.
    Marchetti, P.
    Cantore, M.
    Zaniboni, A.
    Rimassa, L.
    Ciuffreda, L.
    Ferrari, D.
    Zagonel, V
    Maiello, E.
    Sobrero, A.
    ANNALS OF ONCOLOGY, 2021, 32 (01) : 66 - 76
  • [10] Patients' preferences for adjuvant chemotherapy in early breast cancer: a review of what makes it worthwhile
    Duric, V
    Stockler, M
    LANCET ONCOLOGY, 2001, 2 (11): : 691 - 697
12345